Literature DB >> 1824246

Breakpoint clustering in t(4;11)(q21;q23) acute leukemia.

C S Chen1, P S Medberry, D C Arthur, J H Kersey.   

Abstract

Chromosome 11 band q23 is commonly involved in nonrandom chromosomal translocations in hematopoietic malignancies, especially in infant acute leukemias. By using pulsed-field gel electrophoresis (PFGE) with restriction endonuclease digests of DNA from both a leukemia cell line (RS4;11) bearing the t(4;11)(q21;q23) and from human/hamster hybrid cells, we have been able to construct a detailed restriction map of the chromosome 11q23 region and have localized the t(4;11) chromosome 11 breakpoint to a region located approximately 200 to 230 kb telomeric to the CD3 gamma region and approximately 580 kb centromeric to the PBGD gene. PFGE analyses of DNA from clinical leukemia specimens and cell lines indicated a tight clustering of breakpoints in all eight t(4;11) acute leukemias studied. These data strongly suggest that discrete genetic loci are interrupted on both chromosomes 4 and 11 in a manner likely to be critically involved in the pathogenesis of t(4;11) acute leukemias. To our knowledge, these results represent the first evidence of breakpoint clustering in t(4;11) acute leukemias. In contrast to t(4;11), other 11q23 abnormalities studied to date have frequently shown evidence for alternative breakpoint sites in 11q23.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1824246

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  2 in total

1.  Detection of chromosome 11q23 involving translocations by pulsed field gel electrophoresis.

Authors:  J Finke; R Kunzmann; W Lange
Journal:  Ann Hematol       Date:  1994-03       Impact factor: 3.673

2.  Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes.

Authors:  P H Sorensen; C S Chen; F O Smith; D C Arthur; P H Domer; I D Bernstein; S J Korsmeyer; G D Hammond; J H Kersey
Journal:  J Clin Invest       Date:  1994-01       Impact factor: 14.808

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.